MK-677
Oral Growth Hormone Secretagogue
MK-677 occupies a unique position in GH secretagogue research: it's orally bioavailable, has a long half-life (~24 hours), and stimulates GH release without injection. These properties have made it one of the most extensively studied GH secretagogues outside of injectable peptides.
At a Glance
MK-677 is a non-peptide ghrelin receptor agonist — meaning it mimics ghrelin's action at GHSR-1a to stimulate pituitary GH release, but is stable enough for oral administration and resistant to digestive degradation in ways that injectable peptides are not.
It produces sustained GH elevation rather than sharp pulses, which distinguishes it from GHRP compounds like ipamorelin. This sustained profile has been studied for its effects on IGF-1 levels, body composition, bone density, and sleep architecture.
Phase 2 clinical trials have been conducted for growth hormone deficiency in children and elderly populations, providing a body of human data that is unusual for a compound not yet approved.
This compound operates through several converging biological pathways, which helps explain the breadth of effects observed across different tissue and metabolic models.
Ghrelin Receptor Agonism
Binds GHSR-1a to stimulate pituitary GH secretion — same receptor as injectable GHRPs but orally active due to non-peptide structure.
Sustained GH Elevation
Produces sustained GH rise rather than sharp pulses — a different profile from ipamorelin/CJC-1295 combinations that may suit different research designs.
IGF-1 Upregulation
Consistently elevates IGF-1 in clinical studies — one of the most reliable IGF-1 stimulators in the secretagogue class.
Sleep Architecture Enhancement
Deep slow-wave sleep enhancement observed in clinical studies — consistent with GH's natural role in sleep physiology and recovery.
- Body composition — lean mass preservation and fat mass reduction in aging and GH-deficient models
- GH deficiency research — Phase 2 trials in children and elderly adults
- Bone mineral density — sustained IGF-1 elevation and skeletal effects
- Sleep quality research — slow-wave sleep enhancement in clinical studies
- Muscle wasting (sarcopenia/cachexia) — studied in elderly and cancer patient models
- Fracture healing — IGF-1-mediated effects on bone repair
- Metabolic research — GH axis effects on insulin sensitivity and lipid metabolism
MK-677, ipamorelin, and sermorelin represent different mechanistic approaches to GH axis stimulation, each with distinct research advantages.
| Aspect | MK-677 | Ipamorelin | Sermorelin |
|---|---|---|---|
| Administration | Oral (once daily) | Injectable (2–3x daily) | Injectable (daily) |
| GH Release Pattern | Sustained elevation | Pulsatile (mimics natural) | Pulsatile |
| Half-Life | ~24 hours | ~2 hours | ~10–20 minutes |
| Clinical Data | Phase 2 available | Limited | Phase 3 (approved, discontinued) |
| Research Advantage | Oral, long-duration models | Clean selective pulses | GHRH pathway specificity |
Oral bioavailability — unique among GH secretagogues; eliminates injection burden in long-duration studies
Phase 2 human data available — clinical trial programs provide human evidence base
Consistent IGF-1 elevation — reliable in most studied populations
Appetite stimulation — ghrelin receptor agonism increases hunger, which can confound body composition studies if not controlled for
This overview is strictly educational and based on publicly available scientific literature as of 2026. It does not constitute medical advice. All Helixera Labs products are for laboratory research use only. Not for human or veterinary use. · Helixera Labs LLC © 2026